Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study

BACKGROUND: Both anlotinib and programmed death-1 (PD-1) blockade have been approved for the second-line treatment of metastatic esophageal squamous cell carcinoma (ESCC). However, the combination of these two therapies has not been evaluated. This study investigated the efficacy and safety of anlot...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Ge, Qingqing, Xu, Shuning, Li, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428701/
https://www.ncbi.nlm.nih.gov/pubmed/36059654
http://dx.doi.org/10.3389/fonc.2022.942678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428701/
https://www.ncbi.nlm.nih.gov/pubmed/36059654
http://dx.doi.org/10.3389/fonc.2022.942678

Ejemplares similares